CHEERS-AI Economic Evaluation

By João L. Carapinha

November 5, 2024

NICE (National Institute for Health and Care Excellence) introduces CHEERS-AI! It’s a new reporting standard optimized for health economic evaluations of AI technologies in healthcare. The EU funded CHEERS-AI as part of the Next Generation Health Technology Assessment (HTx) project. Its primary aim is to enhance the transparency and quality of cost-effectiveness studies specifically tailored for AI-enabled healthcare interventions.

Purpose and Background

CHEERS-AI seeks to systematically address the challenges facing health economic evaluations of AI interventions. A systematic review has identified several issues, including poor quality input data, author conflicts of interest, lack of transparent reporting, and vague information regarding AI functionality.

Solution: CHEERS-AI economic evaluation

Building on the established CHEERS 2022 standards, CHEERS-AI incorporates the original 28 standards while adding 8 new details for AI-related nuances and 10 AI-specific standards. The extra standards tackle key aspects such as user autonomy, continuous AI learning, and the methodology behind developing the AI component.

Objectives

The primary goal of CHEERS-AI is to ensure transparent and reproducible reporting of AI-specific details in health economic evaluations. This standard will aid healthcare decision-makers in understanding the value of AI-enabled treatments, ultimately facilitating faster access to promising AI technologies for patients.

Endorsement and Integration

ISPOR endorsed CHEERS-AI and is now included in the EQUATOR Network checklist of reporting guidelines. This endorsement ensures integration into best practices for health economic evaluation reporting.

Impact

Refining the quality and transparency of health economic evaluations involving AI technologies is an important objective. In doing so, CHEERS-AI aims to elevate the standards of economic evaluation reporting. This improvement is vital for reimbursement decisions and the broader adoption of AI in healthcare.

In summary, CHEERS-AI represents an advancement in standardizing and enhancing health economic evaluations of AI technologies, thereby supporting improved decision-making in healthcare.

Reference url

Recent Posts

Mavyret acute hepatitis C
         

Mavyret Acute Hepatitis C: Pioneering Treatment Expansion and Economic Implications

🌟 Did you know that the FDA has just approved the first-ever treatment specifically for acute Hepatitis C?

AbbVie’s Mavyret (glecaprevir/pibrentasvir) is now set to improve the way we think about HCV interventions, enabling earlier treatment to reduce long-term complications and improve patient outcomes. This approval not only addresses an urgent public health need but also aligns with evolving healthcare delivery models focused on cost-effective solutions.

Curious to learn more about the implications of this significant advancement in hepatitis care? Review the full article for insightful analysis on the future of HCV treatment!

#SyenzaNews #HealthcareInnovation #MarketAccess #HealthEconomics

HIV vaccine trials
    

Advancements in HIV Vaccine Trials: Promising Results from mRNA Strategies

🌍 Are we finally making strides in the fight against HIV?

Recent phase 1 vaccine trials using mRNA technology have shown promising results in activating immune responses that could lead to broadly neutralizing antibodies (bnAbs). This innovative approach not only addresses HIV’s rapid mutation but also offers critical insights for high-prevalence regions.

Dive into the full article to explore how these trials could shape the future of HIV prevention and what it means for global health!

#SyenzaNews #globalhealth #HIV #clinicaltrials

EHK clusters 2026 report
       

EHK Clusters 2026 Report: Enhancements in Dutch Risk Equalization for High-Cost Pharmaceuticals

🚀 Are you curious about how the Dutch healthcare system is adapting to high-cost pharmaceuticals?

The latest EHK clusters report for 2026 brings crucial updates to the risk-equalization model, enhancing equity among health insurers while closely managing skyrocketing costs. With innovative clustering techniques and revised reimbursement figures, these changes aim to improve access and accountability in an increasingly competitive healthcare landscape.

Dive into the full article to uncover the implications for health economics and policy!

#SyenzaNews #HealthEconomics #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.